Mental Health Rising controversy over function of FDA and Medicare in selling anti-amyloid medicine given restricted profit, excessive price, extreme side-effects By / June 26, 2023
Mental Health On the 7 Habits of Extremely Stress-Resilient Minds, cognitive screenings, anti-amyloid medication, and extra By / April 30, 2023
Mental Health CMS: anti-amyloid drug Leqembi (lecanemab) would not meet the “cheap and vital” commonplace required for wider Medicare protection By / March 7, 2023
